Humacyte enters $60M at-the-market equity offering with TD Cowen

Humacyte, Inc.

Up to $60M in common stock may be sold from time to time through TD Securities (USA) LLC as agent.
TD Cowen will receive a commission of up to 3.0% of gross proceeds.
Net proceeds to fund commercialization of Symvess in vascular trauma, pipeline, and working capital.
Company is not obligated to sell any shares; ATM allows sales at prevailing market prices.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Humacyte, Inc. entered into Sales Agreement with TD Securities (USA) LLC valued at aggregate offering price of up to $60,000,000 (effective 2025-12-16).

Action: entry
Agreement: atm program
Counterparty: TD Securities (USA) LLC
Value: aggregate offering price of up to $60,000,000
Effective: 2025-12-16

Exact text from the filing

On December 16, 2025, Humacyte, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC, as agent (“TD Cowen”), under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $60 ,000,000 (the “Shares”) during the term of the Agreement through TD Cowen, acting as agent.

View on SEC.gov

Browse all material agreements →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-121674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.